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ABSTRACT
PROGNOSTIC IMPLICATIONS OF PATIENTS WITH MAMMOGRAPHICALLY
OCCULT, EARLY STAGE BREAST CANCER
Tzu-I Jonathan Yang and Meena S. Moran
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT.

Purpose: To compare mammographically occult (MamOcc) and mammographically
positive (MamPos) early-stage breast cancer patients treated with breast-conservation
therapy (BCT), to analyze differences between the two cohorts.
Methods: The 2 cohorts were comprised of 214 MamOcc and 2168 MamPos patients
treated with BCT. Chart reviews were conducted to assess mammogram reports and
method of detection. All clinical–pathologic and outcome parameters were analyzed to
detect differences between the two cohorts.
Results: Median follow-up was 7 years. There were no differences in final margins, T
stage, nodal status, estrogen/progesterone receptor status, or “triple-negative” status.
Significant differences included age at diagnosis (p < 0.0001), more positive family
history (p = 0.0033), less HER-2+ disease (p = 0.0294), and 1° histology (p < 0.0001). At
10 years, the differences in overall survival, cause-specific survival, and distant relapse
between the two groups did not differ significantly. The MamOcc cohort had more breast
relapses (15% vs. 8%; p = 0.0357), but on multivariate analysis this difference was not
significant (hazard ratio 1.0, 95% confidence interval 0.993–1.007, p = 0.9296). Breast
relapses were more commonly not picked up on mammography in the MamOcc cohort
(32% 12% p = 0.0136).
Conclusions: Our study suggests that there are clinical–pathologic variations for the
MamOcc cohort vs. MamPos patients that may potentially affect management, but that
breast relapse rates after BCT are ultimately not significantly different for these 2
cohorts. Breast recurrences were more often mammographically occult in the MamOcc
cohort; consideration should be given to closer follow-up and alternative imaging
strategies (ultrasound, breast MRI) for routine post-treatment examination. To our
knowledge, this represents the largest series addressing the prognostic significance of
MamOcc cancers treated with BCT.
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INTRODUCTION
For early-stage breast cancer, mammography is an integral part of the workup
before definitive treatment. Although diagnostic mammography is the standard breast
imaging method used preoperatively to verify the location and extent of disease and to
determine whether a patient is eligible for breast-conservation therapy (BCT), 9–26% of
patients with breast cancer present with false-negative mammograms (1-4) at the time of
diagnosis. A list of previous studies examining the rate of false-negative mammogram in
women with breast cancer is provided in Table 1. Whether the cause of the negative
result is dense breast tissue, diffuse disease, poor quality of the mammogram, or
oversight of the primary tumor, the prognostic implications of a false-negative
mammogram at presentation are generally unknown.

Table 1: Prevalence of mammographically occult breast cancer in literature.
Author

Total Breast Cancer
Patients (n)

Mammographically
Occult Breast
Cancer Patients (n)

Percentage of
Mammographically
Occult Brest Cancer
Patients (%)

Wallis et al. (1)

75

871

9

Feig et al. (2)

138

20

14

Edeiken et al. (3)

108

499

22

Niloff et al. (4)

160

41

26

Samuels et al. (5)

55

542

10

Morrow et al. (6)

52

269

19

Voogd et al. (7)

30

165

18
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This thesis provides a summary of current common breast cancer screening
imaging modalities, the clinical benefit of mammography, and predictive values of
abnormalities on mammogram.

It also provides an introduction to the concept of

mammographic sensitivity, mammographically occult breast cancer, and the utilization of
breast conservation therapy (BCT). Lastly, it details our investigation on the clinical and
pathologic features and long-term outcome of patients with mammographically occult
breast cancer.

Screening for Breast Cancer
Approximately 207,090 women in the United States are diagnosed with invasive
breast cancer annually (8), with the majority of the breast cancers diagnosed as a result of
an abnormal screening study.

A variety of imaging modalities have been used for

detection of breast cancer. Although Mammography has been and remains the primary
imaging modality for the screening of breast cancer in the United States, a percentage of
cancers are not visible mammographically, and it has a lower sensitivity for cancer
detection in dense breast tissues (9). Furthermore, mammographic sensitivity seems to
decrease and is insufficient for early diagnosis of breast cancer in women who are at
increased familial risk with or without documented BRCA mutation (10). These issues
have led to ongoing investigations for alternate imaging modalities in screening for breast
cancer in specific patient populations, such as younger women with dense breast, or
women with strong familial history of breast cancer.
Ultrasound is primarily used for diagnostic follow-up and further clarification of a
questionable lesion and for visual guidance during a needle biopsy. Furthermore, it is
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considered the first line imaging modality for breast imaging in pregnant women or in
women less than 30 years of age with focal breast symptoms. A large, multi-center
prospective study by Berg et al. evaluated the effectiveness of breast cancer screening
using ultrasound in addition to mammography in elevated risk women with
heterogeneously dense breast tissue in at least one quadrant. The authors found that of
the 41 patients who were diagnosed with cancer, 8 demonstrated lesions on both
ultrasound and mammography, 12 were detected by lesions on ultrasound alone, and 12
by mammography alone. The authors concluded that adding a screening ultrasound to
mammography would lead to an additional 1.1-7.2 cancers per 1000 women (11).
Interestingly, in addition to the 29% of the tumors which were mammographically occult,
an additional 20% of participants diagnosed of cancer (8 patients) demonstrated no
abnormality on either the mammogram or ultrasound.
Magnetic resonance imaging (MRI) is an emerging imaging modality for the
screening of breast cancer that is under investigation. Currently MRI, in addition to
mammography, is more commonly utilized among patients who are at high-risk for
developing breast cancer. MRI relies on the increased vascularity of neoplasms and has
been found to have higher sensitivity in detecting breast cancer when compared to
mammography. The sensitivity has been demonstrated to be less dependent on breast
density (12). This makes MRI an attractive screening tool for women with an elevated
risk of developing breast cancer.

In 2008, Warner and colleagues published their

findings of a systemic review on studies after 1994 examining the use of MRI and
mammography for screening of women at very high risk for breast cancer (13). From the
11 prospective studies included in their review, the authors found the sensitivity of
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mammography varied from 14-59% when a positive mammogram was defined as a
Breast Imaging Reporting and Data System (BI-RADS) 4 or 5 score, while the sensitivity
of MRI ranged from 51-100%.

The downside of using MRI routinely to screen all

patients is the lower specificity and higher false positive rate, often warranting additional
work-up (i.e. biopsies).

A recent study by Riedl et al. compared mammography,

ultrasound, and MRI of the breast used for the surveillance of women at high risk for
breast cancer concluded specificities of 98%, 98%, and 92% for mammography,
ultrasound and MRI, respectively. This study also documented the higher false positive
rate of MRI compared to mammography and ultrasound (81% vs. 64%, 68%,
respectively) (14).

Origin and the Clinical Benefit of Mammography
The first x-ray of the breast tissue was obtained in 1913 by Dr. Albert Salomon, a
surgeon who reported the use of radiography of mastectomy specimens that demonstrated
the primary tumors as well as spread to axillary lymph node (15).

In 1949, Dr. Raul

Leborgne was the first to report the significant association of radiographically detectable
microcalcifications and breast carcinoma, reported finding radiographically visible
microcalcifications in 30% of patients with breast cancer and thus setting the stage for
screening mammography.

In 1960, Dr. Robert L. Egan described a kilovoltage

mammographic technique that was easily reproducible, which led to the development and
widespread use of mammography. In 1963, the Cancer Control Program of the U.S.
Public Health Service sponsored a conference at the M.D. Anderson Hospital, reporting
on the usefulness and reproducibility of mammography (15).

The results of a 24
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institutions nationwide mammography study were presented at the conference: the truepositive rate for mammography was 79%, and the false-negative rate was 21% (16). The
results of this study established that other radiologists could learn the technique of
mammography developed by Dr. Robert Egan, that mammography could enable
differentiation between benign and malignant lesions, and that mammography could be
used to screen for cancer in asymptomatic women. Interestingly, despite the more recent
advancements in mammographic techniques, the false-negative rate of mammography
appears to be relatively consistent through the years (see Table 1), indicating the
continuing need for patient selection and investigations of emerging imaging modality in
breast cancer screening.
Mammography became the standard for breast cancer screening in the 1970s. In
1973, Strax and colleagues published their results of a randomized mass screening
program using mammography as well as clinical examination in a group of 62,000
women aged 40 to 60. The authors found that mammography contributed substantially to
the detection of breast cancer. Of 132 breast cancers detected through screening, 44
(33%) were found on mammography only and would have been missed if it were
omitted. At 7-year follow-up, a 33% reduction in mortality rate was attributed to the use
of mammography (17).

In a 2002 Lancet publication, Nyström and colleagues

demonstrated the advantageous effect of breast screening using mammography on breast
cancer mortality after long-term follow-up (15.8 years) of the Swedish randomized
controlled trials. The authors showed a 21% reduction in breast cancer mortality when
comparing women who underwent mammography screening (164,770 patients) to those
who did not (1,688,440 patients).

They demonstrated that the benefit in terms of
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cumulative breast cancer mortality reduction started to emerge at 4 years after
randomization and continued to increase to approximately 10 years. Thereafter, the
benefit in absolute reduction was maintained throughout the period of observation (18).
In a recent Cochrane Database Systemic Review article, Gøtzsche et al. published their
assessment of randomized trials comparing mammographic screening with no
mammographic screening to determine the effect of screening for breast cancer with
mammography on mortality and morbidity. The authors identified seven eligible trials
and included 600,000 women in the analyses and concluded that mammographic
screening is likely to reduce breast cancer mortality with an estimate 15%-20% reduction
corresponding to an absolute risk reduction of 0.05% (19).

From these studies, it is

reasonable to conclude that the implementation of mammography has proven beneficial
in reducing breast cancer related death worldwide.
Recently, there has been a great deal of controversy regarding changes in breast
cancer screening recommendations released by the US Preventive Services Task Force
(USPSTF) in 2009, and one of the recommendations made by the Task Force was to
delay in the initial mammographic screening of asymptomatic women from age 40 to age
50 (20).

Although the analysis of the Task Force included eight randomized trials and

demonstrated an estimate relative risk for breast cancer-associated mortality of 0.85 (95%
CI, 0.75-0.96), or 15% average breast cancer mortality reduction, for women of 39-49
years of age who undergo screening mammography, the Task Force also found that
nearly 1 in 10 women in their 40s had a false-positive result per round of screening.
Eighty percent of the false-positive screening resulted in additional imaging, and 10% of
women with false-positive screenings resulted in biopsy (21). The USPSTF analysis
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recognized the benefits of routine mammography starting at age 40, but the farms in
terms of false-positive results are real as well. Clearly, there is a need of investigations
that can help us better delineate the best imaging modalities in breast cancer screening for
women younger than age 50.

Abnormalities on Mammogram
When mammographic findings that may be associated with breast cancer are
identified at screening, further diagnostic work-up is required. These abnormal findings
often include masses, calcifications, architectural distortion, and asymmetry.

The

accuracy of mammography is directly related to the positive predictive values of the
findings.

A large analysis of the positive predictive value associated with specific

mammographic findings in screening and diagnostic examinations using the San
Francisco Mammography Registry was published by Venkatesan and colleagues in 2009
(22). The study included 10,641 mammograms performed in 20 facilities between 1998
and 2002. The purpose of the study was to evaluate the risk of cancer associated with
specific abnormal findings in mammographic examinations, to determine the distribution
and prevalence of these findings, and to analyze positive predictive value variation
according to user and patient factors. The authors found that masses and calcifications
were the most commonly recording findings. While masses were much more prevalent
(69%) in diagnostic examination, in screening examinations masses, calcifications, and
asymmetry were equally common. Architectural distortion was an uncommon finding for
both screening and diagnostic mammograms. The positive predictive values of specific
mammographic findings are listed in Table 2. The authors concluded that overall, one in
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twenty invasive cancers was identified with asymmetry, one in sixteen invasive cancers
was identified with architectural distortion, one in five invasive cancer was identified
with calcification, and two in three invasive cancers were identified with a mass.

Table 2: Prevalence and positive predictive value of mammographic abnormalities
in breast cancer detection (22).
Screening
Examination
(n=4025)

Mass

Calcifications

Architectural
Distortion

Asymmetry

Incidence (n)

1417

1345

265

998

Prevalence (%)

35.2

33.4

6.6

24.8

Positive
Predictive
Value (%)

9.7

12.7

10.2

19.6

Diagnostic
Examination
(n=6616)

Mass

Calcifications

Architectural
Distortion

Asymmetry

Incidence (n)

4534

1741

108

233

Prevalence (%)

68.5

26.3

1.6

3.5

Positive
Predictive
Value (%)

19.6

24.1

60.2

14.6

Mammographic Sensitivity
Although mammography remains the primary imaging modality for breast cancer
screening, it remains limited in its ability to detect all cancers; its sensitivity ranges from
60-98% and has been reported to be as low as 30% in women with dense breasts (23-26).
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In 1996, Kerlikowske and colleagues published a large cross-sectional study on
mammography and the effects of patient’s age and breast density on its sensitivity(25).
The study, with over 20,000 women aged 30 years and older who underwent
mammographic screening from 1985 to 1992, had 238 women who were subsequently
diagnosed with breast cancer.

The authors found that the sensitivity of screening

mammography was the highest for women ages 50 or older with primarily fatty breasts
compared to dense breasts (98.4% vs. 83.7%). For women less than 50 years of age, the
study suggested that breast density did not seem to affect the sensitivity of
mammography (81.8% for women with primarily fatty breast, 85.4% for women with
dense breast).

When the patients were further stratified by age, mammographic

sensitivity was lower in women of younger age (see Table 3).

Table 3: Sensitivity of screening mammography of all breast cancer (25).
Age Range (y)

30-39

40-49

50-59

60-69

≥ 70

Mammographic
Examinations (n)

7306

8833

4631

3402

1885

Breast
Cancer
Incidence (n)

22

45

47

51

34

77.3

86.7

83.6

94.1

91.2

Sensitivity (%)

The authors concluded that the lower sensitivity of mammography in younger
women was due primarily to the more aggressive tumors in younger women, and was not
due to denser breast tissue as the sensitivity of screening mammography decreased with
increasing size of tumor, and a lower sensitivity for detecting large tumors is more
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pronounced in younger than in older women. But contradicting these results, other studies
have suggested that breast density is, in fact, a significant predictor of mammographic
detections (26, 27).

In Kolb and colleagues’ investigation comparing screening

mammography, physical examination, and breast ultrasound, the authors found that
mammographic sensitivity declined significantly with increasing density and in younger
women with dense breast, and these effects were independent.

The sensitivity of

mammography for women 49 years or younger and 50 years or older were 58% and 83%,
respectively. The sensitivity of mammography for women with breast density decreased
from densities less than 25% having 98% sensitivity, versus 25-50% breast density with
83% sensitivity; 51-75% breast density with 64% sensitivity, and more than 75% breast
density with 48% sensitivity (27).
More recently, Ernster et al. analyzed 653,833 mammograms of 540,738 women
between 40 and 84 years of age screened between 1996 and 1997 from the
mammography registries of the Breast Cancer Surveillance Consortium (28).

The

purpose of their study was to determine mammography’s role and ability in the screening
and detection of ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer.
While doing so, the authors also provided findings for invasive breast cancer. They
determined that the sensitivity of screening mammography for all patients was higher for
DCIS than it was for invasive breast cancer (86% vs. 75%, respectively). Table 4 details
the percentages of positive screen stratified by patients’ age in their investigation.

The

authors concluded that approximately 1 in every 1300 screening mammograms leads to a
diagnosis of DCIS. The increased sensitivity in detecting DCIS when compared to
invasive breast cancer could be attributed to the microcalcifications associate with DCIS.
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In dense or heterogeneously dense breast tissue, microcalcifications are easier to detect
on mammograms and the DCIS may never become clinically apparent, thus potentially
biasing the sensitivity for detecting DCIS upward.

Table 4: Mammographic sensitivity in detecting DCIS and invasive cancer (28).
Age Range (y)

40-49

50-59

60-69

70-84

211551

200255

135376

106651

DCIS
Cases Diagnosed (n)

134

155

165

137

DCIS
Sensitivity (%)

88

88

84

83

Invasive Cancer
Cases diagnosed (N)

450

792

709

724

Invasive Cancer
Sensitivity (%)

67

72

76

83

Mammographic
Examinations (n)

From the above studies, it is reasonable to conclude that mammography is
effective in screening for both DCIS and invasive breast cancer, however, its sensitivity
for the detection of invasive cancer correlates positively with patient’s age and negatively
with breast density.

Breast density itself is a major independent risk factor for breast

cancer that cannot be explained by the masking of cancers by dense breast tissue (29),
and previous studies suggested that younger patients who presented with false negative
mammograms could represent a more aggressive form of cancer (25, 30). Therefore it is
necessary to understand the pathology of mammographically occult breast cancer and to
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evaluate its prognostic indication and to determine the most suitable treatment for
patients diagnosed with mammographically occult tumors.

Other Factors Associated with Mammographically Occult Breast Cancer
Although false negative mammogram is often attributed to dense breast
parenchyma in younger patients, inadequate radiographic technique, observer error, and
diffuse tumor histology have also been suggested (1, 31, 32). In an early study by
Holland et al., the authors suggested that tumors of diffuse invasive type with poorly
outlined mass, such as invasive lobular carcinomas with poor desmoplastic reaction, may
lead to false negative mammograms, even in an advanced stage (33). This same finding
of diffuse histology leading to a highly risk of false negative mammographic screening
was also reported by Hollingsworth et al. (32). Morrow and colleagues in 1997 showed
that particular histological tumor types, such as tubular carcinoma (13.5% of
mammographically occult tumors and 1.8% of mammographically evident tumors), are
more often associated with mammographically occult breast carcinoma (6). In another
investigation, Wallis et al. noted that 5.5% of mammographically occult carcinomas had
medullary histology compared with 0.8% of their mammographically evident cohort (1).

Breast Conservation Therapy
To be able to evaluate the appropriate treatment for patients diagnosed with early
stage mammographically occult breast carcinoma, the current standard of care for early
stage breast cancer patients must be understood. Surgery today remains an integral part
of early stage breast cancer management.

As an alternative to mastectomy, breast-
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conserving therapy (BCT) has been found to be the therapeutic equivalent of total
mastectomy in early breast cancer patients through many randomized trials (34-39). In
BCT, the tumor is first removed with a margin of normal tissue, followed by whole breast
irradiation (WBI). Radiotherapy (RT) has been proven to be effective in improving local
control and long-term survival (40-45). Several key randomized studies are shown in
Table 5. In 2002, Fisher and colleagues published their twenty-year follow up of the
National Surgical Adjuvant Breast and Bowel Project (NSABP) B-04 randomized trial
comparing total mastectomy, wide local resection, and wide local resection plus breast
radiation (36). Between 1976 and 1986, a total of 2163 patients with stage I or II breast
carcinoma were assigned to one of the three arms: mastectomy, lumpectomy, or
lumpectomy plus 50 Gy of radiation to the whole breast.

The authors at twenty-year

follow up concluded that lumpectomy followed by breast irradiation continues to be an
appropriate treatment for women with early stage breast cancer. Some of the significant
findings of the recent publication included a significantly higher ipsilateral breast
recurrence rate for women who underwent lumpectomy and without WBI (39.2% vs.
14.3% in women who underwent lumpectomy and breast irradiation), demonstrating the
benefit of local control with radiotherapy to the intact breast. There were no significant
differences in disease-free survival, distant-disease-free survival, or overall survival
amongst the three groups of women. The hazard ratio for death among the women who
underwent lumpectomy followed by breast irradiation as compared to mastectomy was
0.97 (95% CI, 0.83-1.14; p=0.74).
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Table 5:

Selected randomized trials of breast-conserving therapy versus

mastectomy
Authors

Patients
(n)

Average
Length of
Follow-up
(y)

Local
Recurrence
With Radiation
Therapy (%)

Local
Recurrence
Without
Radiation
Therapy (%)

Veronesi et al. (39)

567

10

5.83

23.5

Liljegren et al. (46)

381

10

8.5

23

Fisher et al. (36)

930

20

14.3

39.2

More recently, the addition of a boost to the tumor bed was found to further
decrease local recurrence rate (47, 48). Bartelink and colleagues published their ten-year
follow up of the randomized boost versus no boost European Organisation for Research
and Treatment of Cancer (EORTC) 22881-10882 trial in 2007 (49). The study included
5318 patients who underwent lumpectomy followed by WBI to 50 Gy and were
randomly assigned to receive either a boost of 16 Gy or no boost. At 10 years, the
incidence of local recurrence for the patients who did not receive boost irradiation was
10.2%, and for the patients who received boost irradiation it was 6.2%. Subsequent subset analysis revealed that while the absolute risk reduction was the greatest in young
women (<40 years of age) and high-grade tumors, a statistically significant benefit existed
in all patients. Furthermore, the number of salvage mastectomies was reduced by 41%
with the use of a boost.
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Table 6: Selected randomized trials of boost versus no boost following whole
breast irradiation
Authors

Patients Boost
(n)
(Gy)

Average
Local
Length of Recurrence
Follow-up With Boost
(y)
(%)

Local
Recurrence
Without
Boost (%)

Bartelink et al. (49)

2661

16

10

6.2

10.2

Romestaing et al. (48)

521

10

5

3.6

4.5

From these investigations, breast conservation therapy has become a standard
alternative to mastectomy in patients with early stage breast cancer. Contraindications to
a breast conserving approach include: persistent positive resection margins, multicentric
disease defined as two or more tumors in separate breast quadrants, diffuse malignant–
appearing microcalcifications, history of prior radiation therapy to a field that includes
the affected breast, or pregnancy. It is important to note that there is no consensus on
whether mammographically occult breast carcinoma should be not considered as a
contraindication to breast-conserving therapy at this point.

BCT for Patients with Mammographically Occult Breast Cancer
For patients who present with mammographically occult primary tumors
(MamOcc) who opt for a breast conserving approach, it is unclear whether the
presentation of MamOcc disease confers a worse outcome in terms of local control. Data
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on outcomes after BCT are limited, with some studies suggesting that patients with
palpable disease and false-negative mammograms have a higher risk of diffuse or
extensive disease and implying that these MamOcc patients may be poor candidates for
BCT (32) while other studies suggest that MamOcc patients remain candidates for BCT
(5, 6, 50). Furthermore, issues regarding how to conduct long-term follow-up and detect
future breast recurrences for patients initially undetected by mammography have evoked
concern physicians and patients alike.
In 1992, Samuels and colleagues published their experience with 542 patients
with breast cancer treated with breast conserving therapy, of which 55 presented with
MamOcc disease (5). The local recurrence, 5-year actuarial survival, and 5-year diseasefree survival rates did not differ significant between the mammographically occult and
mammographically evident cohorts (see Table 7). The authors concluded that BCT is an
appropriate treatment for patients with palpable but mammographically negative early
stage breast cancer. Similar conclusions were reached by Rajentheran et al. in their
cohort of patients with 18-month follow up (50). Finally, Morrow et al. found in their
series of MamOcc cases that mammographically occult tumors were not associated with
factors such as size, unfavorable histology, or multicentrity and therefore concluded that
patients with mammographically negative early stage breast cancers are still candidates
for BCT (6).
The above studies suggest

that

BCT

is

suitable for

patients with

mammographically negative early stage breast cancer. However, a histologic study of
patients presenting with MamOcc disease by Hollingsworth et al. reported that a
principal finding of patients presenting with false-negative mammograms is the diffuse
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histology of the primary tumors (32). Voogd et al. reported in their series that
mammographically occult breast cancers are associated with higher local recurrence rate
after breast conserving therapy (7).

These studies indicate that BCT may be

contraindicated in patients with mammographically occult tumors.

Table 7: Local recurrence and survival of patients with mammographically occult
and mammographically positive early stage breast cancers after BCT (6).
Patients
(n)

Local
Recurrence
(%)

5-year Actuarial
Survival (%)

5-year Disease
Free Survival
(%)

Mammographically
Occult Patients

55

10.9

79

94

Mammographically
Positive Patients

219

10.5

79

84
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STATEMENT OF PURPOSE
In this study, we examined our large institutional experience of early-stage breast
cancer patients treated with BCT who initially presented with MamOcc disease,
compared with patients who presented with positive mammograms (MamPos), to
examine the clinical and pathologic features and long-term outcomes of these two groups
of patients. Magnetic resonance imaging of the breast was not used in any of our patients
as a method of detection in this study. In addition, we analyzed the recurrence patterns of
these two cohorts of patients to determine the implications for follow-up for MamOcc
patients who are treated with BCT.
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METHODS AND MATERIALS
Patient Selection
Between the years of 1974 and 2003, 214 MamOcc and 2168 MamPos patients
with early-stage breast carcinoma underwent BCT at the Yale University School of
Medicine, Department of Therapeutic Radiology. These two groups of patients
constituted our study and reference cohorts, respectively, and were the focus of our study.
After approval from the Human Investigations Committee was obtained, a chart review
was conducted for assessment of mammogram reports and method of tumor detection for
all available patients within our database, to confirm the MamOcc cohort. In addition,
clinical parameters (method of tumor detection, age of diagnosis, family history),
pathologic factors (T stage, nodal status, margin status, histology, expression of estrogen,
progesterone, and HER-2 receptors) and outcomes (local–regional relapse, distant
relapse, and overall survival) were recorded. Because of the era in which these patients
were treated, the vast majority had axillary lymph node dissection. For those who did not
have axillary lymph node dissection, axillary radiotherapy was delivered to treat the
axillary contents. All patients received a median dose of 48 Gy to the whole breast,
followed by a boost, for a median total dose of 64 Gy. Regional nodal radiation was
delivered as clinically indicated and has been previously described (51-53). Systemic
therapy was delivered at the discretion of the treating physicians. All patients who were
non-Caucasian were excluded from our outcomes analysis to ensure that race would not
confound results, because the frequency of non-white vs. white patients was different for
the MamOcc cohort (5.6% vs. 11.32%; p = 0.0354). Of the 2 cohorts, the white
population was comprised of 202 MamOcc and 1918 MamPos patients.
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Statistical analysis
All clinical and pathologic features of the two cohorts were entered into a
database and analyzed using SAS 9.1 (SAS Institute, Cary, NC). All tests of statistical
significance were two-sided, and p values of <0.05 were considered statistically
significant.

Bivariate

analyses

for

the

association

between

covariables

and

MamOcc/MamPos were performed using χ2 and Fisher exact tests. The outcome
parameters analyzed included breast relapse–free survival (defined as time from
diagnosis to recurrent disease within the breast), distant recurrence–free survival (time of
diagnosis to disease failure outside the local–regional area), cause-specific survival
(interval from the date of diagnosis to the date of death from breast cancer or to the last
follow-up date), and overall survival (interval between date of diagnosis and death).
Comparison of clinical and pathologic characteristics between the MamOcc and MamPos
groups was done using χ2 analysis. The outcome endpoints were calculated using
standard life-table methods, and the differences were compared using Cox regression
models. The outcome parameters were analyzed by multivariate analysis incorporating
method of tumor detection, age at diagnosis, T stage, nodal status, margin status, HER2/neu status, and triple-negative status into the regression model.
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RESULTS
Median follow-up was 8.4 years for MamOcc patients and 6.6 years for MamPos
patients. The method of presentation for the 202 MamOcc patients was a palpable mass
in all cases; there were no patients with T0 N+ (completely occult primary tumors
presenting with lymph node involvement) in this analysis. The incidence of MamOcc
over the study period in 4-year increments from 1975 to 2003 is shown in Fig. 1. The
highest incidence occurred in the mid-1980s and then seems to have decreased over time.
There were no significant differences in final margin status, T stage, or nodal status for
the MamOcc vs. MamPos groups. The age at diagnosis differed significantly for the two
cohorts; specifically, more patients in the MamOcc group presented at a young age (age
≤40 years) than in the MamPos group (31% vs. 11%, p < 0.0001). The MamOcc group
reported positive family history more often than patients in the MamPos cohort (46% vs.
35%, p = 0.0033). Although all patients had invasive carcinoma, the primary histology of
the tumor differed between the two cohorts, with the MamOcc patients having a higher
incidence of infiltrating lobular carcinoma (12% vs. 5%) and a lower association with
ductal carcinoma in situ (2% vs. 17%) when compared with the MamPos group (p <
0.0001). Although the percentages of patients who were estrogen receptor positive,
progesterone receptor positive, and triple negative (estrogen, progesterone, and HER2/neu negative) did not differ significantly between the two groups, the MamOcc patients
were HER-2 positive less often (14% vs. 29%, p = 0.0294). Table 2 summarizes the
clinical and pathologic tumor characteristics of the MamOcc and MamPos cohorts.
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Table 7: Clinical and pathologic characteristics of MamOcc vs. MamPos.
Parameter

MamOcc
n (%)

MamPos
n (%)

Age at diagnosis
< 40 years
> 40 years

66 (31)
148 (69)

246 (11)
1922 (89)

Family History
Positive
Negative

87 (46)
101 (54)

682 (35)
1250 (65)

Primary Histology
IDC
ILC
Associated DCIS

160 (76)
26 (12)
5 (2)

1495 (78)
112 (5)
322 (15)

p value

<0.0001

0.003

<0.0001

Margin

0.975
Positive
Negative

36 (26)
102 (74)

384 (26)
1095 (74)

T1
T2

153(81)
36 (19)

1512 (80)
372 (20)

Positive
Negative

43 (26)
125 (74)

334 (26)
971 (74)

Stage

0.818

Node

0.999

ER

0.215
Positive
Negative

95 (57)
71 (43)

995 (62)
606 (38)

PR

0.379
Positive
Negative

74 (48)
79 (52)

758 (52)
697 (48)

Positive
Negative

7 (14%)
44 (86)

128 (29%)
320 (71%)

14 (15)
82 (85)

87 (9)
907 (91)

HER-2

Triple Negative
Yes
No

0.029
0.060
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Abbreviations:
MamOcc=
mammographically
occult
cohort;
MamPos=
mammographically positive cohort; ILC= infiltrating lobular carcinoma; DCIS= ductal
carcinoma in situ; ER= estrogen receptor; PR= progesterone receptor; HER-2= human
epidermal growth factor receptor 2.
Treatment parameters for the two cohorts were as follows: median dose to tumor
bed was 64 Gy in both cohorts. All patients in the two cohorts underwent either axillary
nodal dissection or radiation to the full axilla. There were differences in the percentages
of patients who received chemotherapy (35% vs. 26%; p = 0.007) and adjuvant hormonal
therapy (25% vs. 33%; p = 0.0135) for the MamOcc vs. MamPos cohorts, respectively.
At 10 years there were no significant differences in survival outcomes between the two
cohorts (overall survival, p = 0.693; cause-specific survival, p = 0.183). The distant
metastasis rate between the two cohorts did not differ significantly (16% vs. 12%; p =
0.586).
Patients of the MamOcc cohort had a significantly higher breast relapse rate (15%
vs. 8%; p = 0.036) compared with the MamPos patients and more nodal relapse (4% vs.
1%; p = 0.008). The clinical outcomes of the MamOcc and MamPos cohorts at 10 years
are detailed in Table 3, and the survival curves are shown in Fig. 2.

Table 8: Clinical outcomes at 10 Years.
Outcome Parameter

MamOcc (%)

MamPos (%)

p value

Breast Relapse Free Survival

85

92

0.036

Nodal Relapse Free Survival

96

99

0.008

Distant Disease Free Survival

84

88

0.586

Cause Specific Survival

85

91

0.183
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Abbreviations: abbreviations as in Table 7.
When method of detection, age at diagnosis, T stage, nodal status, margin status,
and HER-2 and triple-negative status were incorporated into the multivariate regression
model, MamOcc disease was not an independent predictor of breast relapse–free survival
(hazard ratio 1.0, 95% confidence interval 0.993–1.007, p = 0.9296) but remained an
independent predictor of nodal relapse–free survival (hazard ratio 0.987, 95% confidence
interval 0.975–1.000, p = 0.0483), as shown in Table 4 and Table 5.

Table 9: Results of multivariate Cox regression analysis for local control- Breast
relapse-free survival.
Variables

Hazard ratio (95% CI)

Mammography
Positive
Negative

p value
0.9296

1.0 (referent)
1.0 (0.993-1.007)

Age

0.8359
< 40
> 40

0.935 (0.494-1.768)
1.0 (referent)

T1
T2

1.0 (referent)
1.666 (0.878-3.163)

Tumor Size

0.1184

Nodal Status

0.9977
Negative
Positive

Surgical Margin
Negative
Positive

1.0 (referent)
1.0 (0.858-1.166)
0.0079
1.0 (referent)
1.203 (1.050-1.378)

HER2

0.3702
Negative

1.0 (referent)
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Positive
Triple Negative
Negative
Positive

1.366 (0.691-2.702)
0.9014
1.0 (referent)
0.953 (0.444-2.046)

Abbreviations: HR= hazard ratio; CI= confidence interval; other abbreviations as in
Table 7.
Table 10: Results of multivariate Cox regression analysis for local control- Nodal
relapse-free survival.
Variables

Hazard ratio (95% CI)

Mammography
Positive
Negative

p value
0.0483

1.0 (referent)
0.987 (0.975-1.000)

Age

0.1433
< 40
> 40

2.677 (0.716-10.004)
1.0 (referent)

T1
T2

1.0 (referent)
4.525 (1.133-18.074)

Tumor Size

0.0326

Nodal Status

0.1836
Negative
Positive

Surgical Margin
Negative
Positive

1.0 (referent)
1.278 (0.890-1.279)
0.3907
1.0 (referent)
0.840 (0.563-1.251)

HER2

0.8750
Negative
Positive

1.0 (referent)
0.866 (0.144-5.205)

Triple Negative
Negative
Positive

1.0 (referent)
0.460 (0.101-2.095)

0.3152
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Abbreviations: abbreviations as in Table 9 and Table 7.
Of the MamOcc patients who sustained a breast recurrence, 32% (8 of 25) had a
false-negative/mammographically occult tumor at the time of relapse. This contrasted
with the MamPos patients, of whom only 13% (19 of 150) had falsenegative/mammographically occult tumors at local relapse. This difference in falsenegative mammograms at time of recurrence for the MamOcc and MamPos cohorts
achieved statistical significance (p = 0.0136).
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DISCUSSION
Although mammography is the current standard method for breast imaging before
definitive treatment for early-stage breast cancer, a fraction of patients will have primary
tumors that are mammographically occult. The actual percentage of patients presenting
with mammographically occult primary tumors at diagnosis has been stated to be as high
as 35% in younger women (54) but generally is quoted to be in the range of 9–22% (1-4).
Unfortunately, the long-term prognostic implications for early-stage breast cancer
patients who present with mammographically occult tumors and who choose BCT is
largely unknown. Most studies on MamOcc disease have focused on radiographic
analysis, concentrating on retrospectively reviewing mammograms after the diagnosis of
breast cancer to discern whether the primary tumor was initially missed. Although several
smaller studies have attempted to address recurrence after BCT for MamOcc patients, to
the best of our knowledge our study represents the largest series of MamOcc patients
treated with conservative surgery and radiotherapy and characterizes differences in longterm outcomes, as well as clinical and pathologic characteristics between MamOcc and
MamPos patients.
Several

smaller

studies have attempted

to

analyze clinical–pathologic

characteristics, outcomes, and recurrence patterns in MamOcc patients after BCT. In
1992, Samuels et al. (5) reported on outcomes and recurrences after BCT for MamOcc
patients by analyzing 55 MamOcc and 487 MamPos patients who had undergone
conservative surgery and radiotherapy. Consistent with our findings, they found that
MamOcc patients presented at a younger age, with no difference in T stage and nodal
status. They did not find any significant differences in local–regional control, distant
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metastasis, or overall survival, and concluded that BCT is a suitable treatment option for
MamOcc patients. Furthermore, in direct contrast to our findings, evaluation of
mammograms at recurrence led them to conclude that “negative mammograms at the
time of diagnosis are not predictive of a negative mammogram at recurrence.” It is
possible that the differences in our findings are due to the significantly larger sample
sizes of our two cohorts. Because our study had four times as many subjects as that of
Samuels et al., we had greater statistical power to detect a difference.
In 1999, Voogd et al. (7) took another approach to address the topic of BCT and
MamOcc patients. They identified 39 patients who had local recurrence after BCT and
126 randomly chosen patients without recurrence after conservative therapy, and
reviewed all the reports from the initial and recurrence mammograms. They demonstrated
that patients who presented initially with mammographically occult primary tumors had a
higher risk of local recurrence after BCT, although the difference was only significant for
patients aged <50 years. Again, the sample size for the MamOcc group was small (30
patients), and there were only 4 patients in the cohort who were older than 50 years. They
attempted to find an explanation for the association between mammographic findings and
local recurrence by performing a central pathology review but did not find any factors
that could potentially explain the increase in relapse for the MamOcc cohort.
In a 2008 study, Weinstein et al. (55) characterized mammographic finding in
patients who had undergone BCT and sustained a local relapse. Of their 26 patients who
initially presented with MamOcc disease and developed a breast relapse, 23.1% had
mammographically occult recurrences, which did not differ significantly from their
cohort of recurrent patients who were initially MamPos. They concluded that “the
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mammographic appearance of the original tumor does not always correlate with the
recurrent tumor.” In contrast, Burrell et al. (56) retrospectively reviewed 31 patients with
recurrent tumors and found a high concordance with the characteristics of the original
mammogram. Because of the differences in design of these studies, neither of these
publications spoke directly to the question of the characteristics of MamOcc patients who
had undergone BCT but instead looked to characterize mammographic features of
patients with recurrence.
In the present study we found a younger age at presentation, more invasive
lobular histology, and less association with ductal carcinoma in situ in our MamOcc
cohort, consistent with findings in other studies (2, 6, 31, 57).

We also found a

significant difference in the incidence of self-reported positive family history between
our MamOcc and MamPos cohort, and less HER-2/neu–positive disease. It is notable that
we did not find a difference in primary T stage of the tumor (i.e. T1 vs. T2 disease) or
more nodal involvement in the MamOcc cohort.
In addition, the negative margin rate between the two cohorts was comparable, a
finding of particular importance because mammography has been the standard tool used
by surgeons to delineate the location and extent of disease to determine whether a patient
will be a candidate for successful breast-conserving surgery. In our series, the percentage
of patients with positive margins in both cohorts was exactly equal, which suggests that
false-negative mammograms at presentation are not a predictor for positive margins (or
inability to completely excise the primary tumor). It is important to note that our two
cohorts were treated over a span of nearly 3 decades, in an era in which MRI of the breast
was not available for routine use at our institution. Our mammographically occult cohort
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generally went directly to biopsy (with or without ultrasound). With the frequent use of
MRI in our current practices, contemporary workup for a MamOcc patient seen in our
clinics today would likely result in positive MRI findings. Furthermore, with the current
widespread use of breast MRI, it is even more unlikely that there would be any
differences in outcomes for patients treated today.
We did note that the delivery of systemic therapy differed for the MamOcc and
the MamPos cohorts. The MamOcc patients received more chemotherapy, and the
MamPos patients received more adjuvant hormone therapy. This is likely explained by
the fact that the MamOcc patients were younger and were therefore given chemotherapy
more frequently and received hormones less frequently, although we did not find a
difference in the estrogen/progesterone receptor status of the two study cohorts. Our
outcomes analysis suggests there is no difference in distant disease–free survival, causespecific survival, or overall survival between the two cohorts at 10 years. Although the
differences we noted in breast relapse–free survival were statistically significant on
univariate analysis, mammographically occult primary tumors at diagnosis were not an
independent predictor of local relapse on multivariate analysis when taking into account
the other confounding factors. MamOcc disease remained an independent predictor of
nodal recurrence on multivariate analysis, but because the numbers of nodal relapses
overall were very small, no firm conclusions can be drawn from these data as to the cause
of increased nodal relapses in MamOcc patients.
An important finding of our study is the lower mammographic detectability of the
recurrent cancers in the MamOcc cohort after BCT. These results lead us to conclude that
clinical and pathologic differences in the MamOcc and MamPos patients ultimately result

31
in more false-negative mammograms at recurrence for the MamOcc cohort, suggesting
that this population of patients should be considered for closer clinical follow-up and
alternative imaging strategies, such as ultrasound and breast MRI after BCT.
There are several limitations to our study that warrant further discussion. Intrinsic to the
nature of all retrospective studies, selection biases cannot be entirely accounted for.
Furthermore, although the number of patients in our cohorts was relatively large, it is
possible that the differences in outcomes did not achieve statistical significance owing to
the study being underpowered. Most importantly, although a review of all mammogram
reports was conducted to verify the MamOcc cohort, we did not conduct a central review
of the actual mammograms to determine what percentage of these mammographically
occult tumors were due to “radiological oversight.” In addition, the use of other imaging
modalities (i.e., breast ultrasound) was not evaluated in this study.
Finally, our study is based on a single-institution experience, and multiinstitutional evaluation of larger patient population is needed to eliminate biases based on
differences that may exist in patient demographics, diagnostic procedures, and
therapeutic interventions from one institution to the next.
In conclusion, our series suggests that there are clinical–pathologic differences in
MamOcc vs. MamPos patients that may ultimately affect management and outcomes.
MamOcc patients present at a younger age, have invasive lobular histology more often,
are less often associated with ductal carcinoma in situ, and have less HER-2/neu–positive
disease. Although local control does not seem to be compromised in MamOcc patients
undergoing BCT, these patients have a higher tendency to have false-negative
mammograms at the time of breast recurrence and therefore should be considered for
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closer clinical follow-up and alternative imaging strategies, such as ultrasound and breast
MRI, as part of their routine post-treatment examination.
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FIGURES

Fig. 1. Incidence of mammographically occult (MamOcc) patients over the study period
1975–2003 as a percentage of the total.
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Fig. 2. Ten-year clinical outcomes of mammographically occult (red) and
mammographically positive (black) cohorts. (a) Breast relapse–free survival; (b) nodal
relapse–free survival; (c) disease-free survival; (d) cause-specific survival; (e) overall
survival.

